Miradol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Miradol

What is Miradol? (Composition: Sulpiride)

Property Description
Active ingredient Sulpiride
Form Tablet, Capsule, Oral liquid, Injectable solution
Pharmacological class Atypical Antipsychotic, Neuroleptic
General purpose Management of mood, thought, and behavioral disturbances
Origin Synthetic Benzamide Derivative

What Type of Medicine is Miradol and What is its Composition?

Miradol is a prescription-only medication primarily classified as an atypical antipsychotic, positioning it within the broader neuroleptic drug category. Its identity is defined by the sole active ingredient, Sulpiride (INN), which is a synthetic benzamide derivative.

The compound, Sulpiride, belongs chemically to the benzamide drug group. This medication stands out because its pharmacological profile involves modulating dopamine activity, lending support to its use for central nervous system stabilization.

In What Forms is Miradol Available?

Miradol is produced in multiple pharmaceutical preparations to ensure flexibility for both short-term and ongoing treatment. The primary forms are the oral tablet and the capsule, designed for standard oral consumption.

For alternative administration, this medication is also available as an oral liquid medicine and a solution for intramuscular injection, which supports the alternative parenteral route. This range of forms is a differentiating factor that ensures uninterrupted delivery of the active substance, Sulpiride, even when patients may struggle with solid forms.

What is the General Purpose of Sulpiride?

The general therapeutic purpose of Miradol is to stabilize thought processes and emotional responses, assisting in the management of complex disturbances related to mood, thought, and behavior. The drug acts as a selective dopamine D2 and D3 receptor antagonist.

This specific antagonism allows it to exert both stabilizing antipsychotic activity and antidepressant activity to manage mood and cognitive functions. The general benefit is the restoration of chemical equilibrium, assisting patients in the overall management of psychiatric conditions.

What side effects are possible with Miradol?

Official Safety Profile Overview

Regulatory documentation for the medicine (Mirvetuximab soravtansine-gynx) is structured to highlight key safety concerns that require careful monitoring and management.

Serious Adverse Reactions and Warnings

The medicine carries a Boxed Warning regarding the risk of Ocular Toxicity, which may include severe vision impairment, corneal disorders (keratopathy), dry eye, and light sensitivity. To manage this, an ophthalmic exam is required before treatment begins and regularly during therapy.

Other serious risks include Pneumonitis (inflammation of the lungs), which can be severe or life-threatening, and Peripheral Neuropathy (nerve damage) leading to numbness or tingling in the hands or feet. Severe forms of these reactions typically require permanent discontinuation of the medicine.

Commonly Reported Side Effects (ge10%)

The most frequently documented side effects by the regulatory agencies include:

  • General: Fatigue.
  • Ocular: Blurred vision, keratopathy, dry eye, and photophobia.
  • Gastrointestinal: Nausea, abdominal pain, diarrhea, and constipation.
  • Nervous System: Peripheral neuropathy.
  • Laboratory Abnormalities: Increased liver enzymes (AST, ALT) and decreased blood cell counts (lymphocytes, hemoglobin, leukocytes).

Specific Safety Considerations

  • Embryo-Fetal Toxicity: The medicine can cause harm to an unborn baby. Females of reproductive potential must use effective contraception during treatment and for a specified time (7 months) after the last dose.
  • Lactation: Breastfeeding is not recommended during treatment and for a period after the final dose.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information regarding overdose is strictly governed by documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). These documents define the exact symptoms, risks, and necessary actions in the event of an ingestion exceeding therapeutic use.

Overdose Scope Official Regulatory Standard (for Miradol)
Documented Overdose Presentations Specific clinical manifestations (signs and symptoms) of overdose with Miradol are not documented in available regulatory filings under this name.
Physiological Systems Affected The regulatory section would typically specify system-wide effects, such as on the central nervous, cardiovascular, or respiratory systems.
Dose-related or Exposure Factors Official labeling would indicate if ingestion of a high dose, or accidental exposure to a modified-release formulation, complicates the management or delays the onset of life-threatening effects.
Population-specific Overdose Notes Any enhanced risk for severe outcomes in specific groups (e.g., pediatric or patients with liver impairment) would be explicitly noted.

When Immediate Medical Help is Required

Official overdose statements consistently emphasize that urgent medical attention must be sought immediately for any suspected overdose. This includes calling emergency services or proceeding to an emergency department without delay. The regulatory mandate is to detail the specific medical management required for toxicity, which may involve the administration of a designated antidote and general supportive measures to stabilize vital functions. This guidance ensures prompt intervention against potentially life-threatening outcomes defined in the product’s official safety profile.

Therapeutic Uses of Miradol

What Miradol Treats: Main Uses and Benefits

Miradol is commonly used within therapeutic areas involving certain distressing symptoms, primarily for conditions where functional stability becomes affected, including the management of major psychotic illness.

It is applied in addressing core manifestations of Schizophrenia, where it helps manage symptom clusters that may become intense or disruptive, such as delusions and hallucinations, as well as deficit states like apathy and emotional flattening. This provides support that helps ease the overall symptom burden and assists with maintaining functional stability during episodes of heightened discomfort.

The medication is also considered relevant for easing symptoms related to affective and mood imbalance, including heightened symptoms of low mood or inner tension, and assists with symptomatic management for specific, disruptive somatic symptoms like persistent vertigo and severe behavioral disorders in children. It contributes to easing discomfort during symptomatic periods and assists with functional stability.


Quick Fact: Relief for Psychotic and Deficit Symptoms The medication plays a role in managing both the agitated (positive) and withdrawn (negative) symptoms of psychotic illness, which assists with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Miradol? (Sulpiride)

The official eligibility for using Miradol is strictly defined by regulatory documents, which list absolute prohibitions and necessary restrictions based on specific medical conditions and patient demographics.


Contraindicated Populations and Conditions

Miradol is contraindicated (must not be used) in patients with specific high-risk conditions, including:

  • Phaeochromocytoma (or suspected phaeochromocytoma).
  • Prolactin-dependent tumours (e.g., prolactinoma or breast cancer) due to the drug's effect on prolactin levels.
  • Known hypersensitivity to sulpiride or its components.
  • Concomitant use with Levodopa or certain dopamine agonists.

Restricted and Conditional Use

Population/Condition Eligibility Status (As per Label)
Pregnancy/Lactation Not recommended during pregnancy and generally contraindicated or not recommended during breastfeeding.
Pediatric Use Not recommended or has insufficient clinical experience to permit use in children under 14 years of age.
Renal Impairment Eligible only with a mandatory dose reduction or adjustment of the dosing interval.
Older Adults Requires particular caution and close monitoring due to increased susceptibility to adverse effects.
Cardiovascular Risk Use requires caution and verification of the absence of risk factors for QT interval prolongation (e.g., hypokalaemia, bradycardia).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Miradol (Sulpiride) is defined by mandatory restrictions and cautions derived from pharmacodynamic and pharmacokinetic patterns documented in official regulatory labeling.

Formal Prohibitions (Contraindications)

Co-administration with Levodopa and dopaminergic antiparkinsonian drugs, such as Ropinirole, is formally contraindicated. This restriction is due to the reciprocal pharmacodynamic antagonism of their effects.

Pharmacodynamic Interaction Risks

Combining Miradol with medicines that affect heart rhythm is generally not recommended. This includes agents that prolong the QT interval or induce bradycardia (slow heart rate), such as specific antiarrhythmics (e.g., Amiodarone), certain antihypertensives (e.g., Diltiazem), and medications that induce hypokalaemia. The concurrent use of Alcohol is restricted as it potentiates the neuroleptic's sedative effects. Caution is also necessary with other CNS depressants (e.g., narcotics, anxiolytics) and antihypertensive agents due to enhanced sedation or increased postural hypotension risks.

Pharmacokinetic Separation Rule

Miradol’s systemic exposure is reduced by agents that interfere with its absorption, including Antacids (aluminum or magnesium hydroxides) and Sucralfate. Regulatory labeling mandates that Miradol must be administered two hours before these products to prevent a significant decrease in drug absorption. No clinically significant interactions based on the cytochrome P450 enzyme system are documented in official prescribing information.

Mechanism of Action

Targeted Modulation of Receptor System X

Miradol's action begins with the targeted interaction and modulation of Receptor System X, which functions as the primary molecular target across specific neural or humoral pathways. This selective engagement initiates a change in signaling dynamics within the pathway, resulting in altered signal conduction.


Adjusting Downstream Signaling Cascades

The initial receptor engagement leads to the modification of downstream molecular cascades, affecting key second messengers and intracellular signaling dynamics. By altering this pathway activity, Miradol modulates processes driven by distinct signaling patterns and results in reduced levels or duration of mediator activity throughout the system.


Modulation of Dysregulated Physiological Processes

Miradol modulates physiological processes characterized by overactive or dysregulated signaling. The drug exerts a controlled, dampening effect that results in the dampening or inhibition of overactive responses within the targeted pathways, which influences subsequent physiological adjustments.

Dosage and Administration Information

Official Administration Guidelines

This section outlines the specific administration instructions for Miradol (pramipexole extended-release), which should be followed precisely as directed by a healthcare provider.

Classification Rule
Route of Administration Oral
Preparation Requirements Tablets must be swallowed whole; do not chew, crush, or divide
Timing in Relation to Meals May be taken once daily, with or without food

Dosing Schedule and Adjustments

Administration begins with a starting dose of 0.375 mg once daily. The dosage may be increased gradually based on individual response and tolerability, but dose increments must occur no more frequently than every 5 to 7 days. The total daily dose should not exceed the maximum recommended amount of 4.5 mg per day.

  • Switching from Immediate-Release: Patients using the immediate-release formulation can be switched overnight to the extended-release tablet at the same total daily dose.
  • Missed Doses: If a significant interruption in therapy has occurred, re-titration of the dosage, starting from a low dose, is warranted to mitigate the risk of adverse events.
  • Renal Impairment: For patients with moderate renal impairment (creatinine clearance between 30 and 50 mL/min), the initial dose is given every other day, with dose adjustments occurring no more frequently than at weekly intervals, and the maximum daily dose is reduced.

The procedural structure for starting treatment requires the daily dose to be increased slowly, ensuring a minimum of 5 days passes between any upward dose adjustment, maintaining the once-daily regimen, and strictly prohibiting the modification of the tablet form.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Miradol (Sulpiride)

The evidence supporting the use of Miradol for its recognized clinical contexts is derived from various types of medical research, primarily systematic reviews and individual clinical trials. These studies were used in research exploring how symptoms change over time and how they are measured by objective scales, providing context but not individual predictions.


Evidence Base for Schizophrenia Management

The research for Miradol relevant in trials assessing short-term or episodic symptom patterns associated with psychotic illness includes both Randomized Controlled Trials (RCTs) and comprehensive systematic reviews and meta-analyses of those trials. The evidence includes observational studies that examined daily-life functioning and were used in research exploring short-term and extended symptom changes.

When studies monitored Miradol against a non-active placebo, the specific randomized trials that explored short-term symptom changes often found that sample sizes were modest and the number of randomized trials available for analysis was limited. For this reason, official sources indicate that certainty remains low regarding the consistency of measured differences compared to placebo in short-term comparisons. The evidence quality varies across studies, and many older RCTs are noted for having limitations in their design or reporting, meaning study results reflect the specific conditions under which they were conducted.


Research on Low Mood and Affective Symptoms

Research explored its use in conditions associated with periods of heightened symptoms, specifically outcomes related to low mood or inner tension. Studies included short-term randomized controlled trials where Miradol was studied for its effect when added to (used as an adjunct to) an existing antidepressant medication.

Given that this evidence often describes its use alongside another medication, the evidence base for its use as a single treatment option (monotherapy) for these outcomes is limited. Long-term effects for this indication are not fully established.


Evidence in Special Contexts and Gaps

Research explored the use of Miradol in specific patient groups, including older adults with psychotic illness, focusing on outcomes describing episodic or acute changes. Studies of Miradol in contexts like vertigo (outcomes related to physical discomfort) are based on smaller, older trials. For the use in children, data for certain groups remain insufficient for establishing specific parameters.

Overall, a key limitation noted in systematic reviews is the comparative evidence is lacking for many direct, long-term comparisons against placebo. Many early sample sizes were modest, and follow-up durations were limited in many pivotal trials, meaning the findings apply only to the populations studied. Research is ongoing to better characterize outcomes related to daily functioning.

Key Studies & References

  1. NICE Guideline on Psychosis and Schizophrenia in adults (relevant section on antipsychotic treatment choice)

Frequently Asked Questions (FAQ)

Common questions about Miradol (FAQ)


Q: Is Miradol the same type of medicine as [similar drug name]? (high-level)

Miradol (Sulpiride) is officially classified as an atypical antipsychotic, also belonging to the broader neuroleptic drug category. This classification defines its core mechanism of action and distinguishes it from medicines in other pharmacological classes. Official documents do not typically provide direct comparisons between Miradol and other individual, named medicines.


Q: Can Miradol be used for conditions other than what's on the label? (Studied for)

In addition to its recognized clinical use, official research evidence states that Miradol has been explored in studies for outcomes related to low mood symptoms when used alongside an antidepressant. The drug has also been studied in older, smaller trials for effects on physical discomfort, such as vertigo.


Q: Is Miradol considered a controlled substance?

Regulatory records indicate that Miradol (Sulpiride) is not classified as a controlled substance by U.S. regulatory authorities. Despite its use in managing central nervous system conditions, its formulation does not fall under the scheduling categories for controlled substances.


Q: What happens if I miss a dose of Miradol?

Official patient information generally advises to skip the missed dose and continue with the next scheduled dose. Regulatory guidance also advises against taking a double dose to make up for a single missed dose.


Q: Does Miradol cause weight gain or loss?

Weight change is a known factor with many medicines that affect the central nervous system. Weight gain is listed as a commonly reported side effect in some official safety documents. Weight loss is not typically noted as a common side effect.


Q: What happens if I accidentally take two Miradol doses close together?

Taking a dose significantly higher than prescribed is considered an overdose, and official advice indicates that medical attention is required. Overdose may lead to symptoms requiring supportive medical care and cardiac monitoring until the patient recovers.


Q: Is there a generic version of Miradol available?

The active ingredient in Miradol is Sulpiride. The substance Sulpiride is widely available and marketed in various countries, which suggests that generic formulations of the active ingredient may be available.


Q: Will Miradol affect my ability to drive or operate machinery?

Official regulatory documents state that Miradol may cause side effects like sedation (drowsiness) which can impair alertness. Official documentation indicates that it may impair the ability to drive vehicles or safely operate machinery.


Q: Are there any long-term effects of taking Miradol?

Studies and systematic reviews note that long-term effects for certain indications are not fully established, as many initial trials had limited follow-up durations. However, regulatory information describes long-term changes associated with the drug class, such as the potential for metabolic changes and elevated prolactin levels (hyperprolactinemia), which are typically subject to regular medical evaluation.


Q: Does Miradol interact with common pain relievers?

Regulatory documents list numerous specific drug interactions, but common non-opioid pain relievers (such as ibuprofen or acetaminophen) are not typically listed among the formally contraindicated or restricted medicines in official patient leaflets.


Q: What is the risk of a serious allergic reaction to Miradol?

Hypersensitivity (an allergic reaction to the drug or its components) is listed as a formal contraindication in official documents. Rare but serious adverse reactions that require immediate medical attention are also documented, such as symptoms of severe blood disorders like agranulocytosis.


Q: How long does Miradol stays in your system after stopping?

Miradol's presence in the system is described using its elimination half-life, which is approximately 7 hours. The half-life refers to the time it takes for half of the drug to be eliminated. It generally takes about 5 half-lives, or around 35 hours, for the medicine to be mostly cleared from the body.


Q: Does Miradol interact with alcohol?

Official regulatory documentation states that the concurrent use of Alcohol is restricted. This is because alcohol can enhance or potentiate the sedative effects of the medicine, leading to increased drowsiness or impairment.


Q: How does Miradol compare to older medicines for the same condition?

Systematic reviews of Miradol note that comparative evidence is lacking for many direct, long-term studies against other medicines. However, some evidence suggests that Miradol may be associated with a lower incidence of certain movement disorders compared to some older antipsychotics.


Q: Does Miradol interact with herbal supplements?

Official patient information leaflets generally advise informing a healthcare provider about taking any other medicines, including any herbal medicines. This is noted as a precautionary measure because herbal supplements may potentially affect how Miradol is processed or acts in the body.


Q: Why is Miradol usually taken at a specific time of day?

To maintain a more consistent level of the medicine throughout the day and to manage potential side effects, Miradol is often prescribed to be taken in divided doses (e.g., morning and evening). This timing helps to balance the drug's action and effects.


Q: Is it normal to feel a bit restless when starting Miradol?

A feeling of intense restlessness, sometimes referred to as akathisia, is a documented side effect associated with Miradol and other similar medicines. This feeling is characterized by an urge to constantly move and an inability to sit still.


Q: Can Miradol cause sensitivity to the sun?

Some official patient information notes that the skin may become more sensitive to sunlight than normal, a condition known as photosensitivity. Official guidance related to photosensitivity often mentions the use of sunscreen or protective clothing to guard the skin from bright or extended sunlight.


Q: Is it true that Miradol can affect sleep patterns?

Yes, regulatory documents describe adverse effects on sleep. Both reports of difficulty sleeping (insomnia) and excessive sleepiness (somnolence or drowsiness) are documented side effects of the medicine.


Q: Is the tiredness caused by Miradol usually temporary?

Tiredness, or sedation, is a common side effect that may be dose-related and can sometimes be managed by adjusting the time the medication is administered. However, regulatory documents do not provide a general timeline for when this common side effect will resolve for all patients.


Q: Can people with liver issues use Miradol?

The elimination of Miradol occurs mainly through the kidneys, which is why mandatory dose adjustments are required for patients with renal (kidney) impairment. Official regulatory guidance regarding patients with liver impairment is limited, and, similar to other drugs cleared by the body, its use in the presence of liver impairment typically requires close evaluation.


Q: What is the primary way Miradol is eliminated from the body?

Regulatory information indicates that the active substance, Sulpiride, is eliminated from the body primarily by the renal route, meaning it is cleared through the kidneys. It is not significantly metabolized (changed) by the liver or other bodily processes.


Q: Are there specific times I should avoid taking Miradol?

To manage potential side effects such as sedation, the medicine is generally dosed to avoid taking a significant portion immediately before activities that require a high degree of concentration or alertness, such as driving.


Q: Can the side effects of Miradol get worse over time?

Official documents note that certain specific side effects, such as the risk of metabolic changes or high prolactin levels (hyperprolactinemia), are associated with long-term use and are typically subject to regular medical evaluation. However, a general statement that all side effects worsen over time is not supported.


Q: Does Miradol change the way other medicines are absorbed?

Miradol does not generally have a major impact on the absorption or metabolism of most other medicines. However, its own absorption is affected by medicines that interfere with stomach acidity, such as Antacids and Sucralfate, which require a separation in administration time.

How should Miradol be stored and disposed of?

Storage and Protection Requirements

Miradol (Sulpiride) must be stored at a temperature that does not exceed 25°C to maintain the stability of the product over its labeled shelf-life. The medicine requires protection from environmental factors; it must be stored in a dry place and away from direct sunlight.

To ensure product integrity, the medication must remain in its original container, which should be kept tightly sealed.

Disposal and Child Safety

As a mandatory safety precaution, Miradol must be stored out of the sight and reach of children and kept in a secure location.

Regulatory instructions prohibit discarding expired or unused product into household waste or drains. Disposal must be carried out in accordance with local regulations for pharmaceutical waste, and users should consult a local waste disposal expert for authorized collection methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Miradol found in:

A-Z Index: